(Total Views: 171)
Posted On: 12/06/2023 12:40:56 PM
Post# of 56

$CHRS News Article - Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress https://marketwirenews.com/news-releases/cohe...21860.html


My Twitter: WhyteStocks